#MedSafetyWeek 2022

During the annual #MedSafetyWeek global campaign, National Pharmaceutical Regulatory Agency (NPRA) collaborates with the Uppsala Monitoring Centre (UMC, the World Health Organisation (WHO) Collaborating Centre for International Drug Monitoring), medicines regulatory authorities, and national pharmacovigilance centres around the world to raise awareness of medication safety and encourage reporting of suspected adverse drug reactions/adverse events following immunisation (ADR/AEFI).

For details, please visit: https://npra.gov.my/index.php/en/health-professionals/medsafetyweek.html